Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity

Part of paid clinical trials in Los Angeles, California.

Sponsor
Jonsson Comprehensive Cancer Center
Study ID
NCT07077239
Status
Recruiting
Apply to this trial

Conditions

  • Prostate Cancer (CRPC)

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Single-arm, prospective registry study assessing changes in acute patient-reported urinary (GU) and gastrointestinal (GI) quality of life at the 24-month post-treatment time point following magnetic resonance imaging (MRI)-guided or computed tomography (CT)-guided stereotactic body radiotherapy (SBRT) delivered to the prostate bed +/- pelvic lymph nodes. The decision to offer an adaptive treatment will be at the clinician's discretion.

Key Dates

Start date
Jul 17, 2025
Status verified
Jul 2025
Primary completion
Aug 1, 2035
Completion
Aug 1, 2036

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Guided Stereotactic Body Radiotherapy
    Patient who has elected to receive SBRT following prostatectomy: eligibility determination based on PSA, pathology, and/or Decipher score

Primary Outcome Measure

Genitourinary Domain Score [ Time Frame: 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California at Los AngelesLos AngelesCalifornia90095
CHRISTY PALODICHUK
[email protected]
310-794-2971
Luca Valle, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By research site
University of California at Los Angeles· Los Angeles, CA

Related Studies